Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M-001 Priming for H5N1 Vaccine in Healthy Adults
NCT02691130Phase 2Completed
- Sponsor
- Scinai Immunotherapeutics Ltd.
- Start
- Nov 2015
- Primary completion
- Oct 2016
- Modality
- Peptides, Peptide-based Cancer Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of multimeric-001 in influenza and Avian influenza H5N1 (H5N1) (3 arms), sponsored by Scinai Immunotherapeutics Ltd. Primary endpoints: Incidence rate of subjects with solicited Adverse Events, Percentage of subjects with Serious Adverse Events and 1 more. Started Nov 2015; status: completed.
02
Drugs
multimeric-001
03
Conditions
influenzaAvian influenza H5N1 (H5N1)
Beyond the preview
Go deeper on NCT02691130.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02691130.